vs
CareDx, Inc.（CDNA）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
CareDx, Inc.的季度营收约是RE/MAX Holdings, Inc.的1.7倍（$117.7M vs $71.1M），CareDx, Inc.净利率更高（2.4% vs 2.0%，领先0.4%），CareDx, Inc.同比增速更快（39.0% vs -1.8%），RE/MAX Holdings, Inc.自由现金流更多（$33.5M vs $514.0K），过去两年CareDx, Inc.的营收复合增速更高（12.9% vs -4.7%）
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
CDNA vs RMAX — 直观对比
营收规模更大
CDNA
是对方的1.7倍
$71.1M
营收增速更快
CDNA
高出40.8%
-1.8%
净利率更高
CDNA
高出0.4%
2.0%
自由现金流更多
RMAX
多$33.0M
$514.0K
两年增速更快
CDNA
近两年复合增速
-4.7%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $117.7M | $71.1M |
| 净利润 | $2.8M | $1.4M |
| 毛利率 | — | — |
| 营业利润率 | 1.0% | 13.1% |
| 净利率 | 2.4% | 2.0% |
| 营收同比 | 39.0% | -1.8% |
| 净利润同比 | — | -75.2% |
| 每股收益（稀释后） | $0.05 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDNARMAX
| Q1 26 | $117.7M | — | ||
| Q4 25 | $108.4M | $71.1M | ||
| Q3 25 | $100.1M | $73.2M | ||
| Q2 25 | $86.7M | $72.8M | ||
| Q1 25 | $84.7M | $74.5M | ||
| Q4 24 | $86.6M | $72.5M | ||
| Q3 24 | $82.9M | $78.5M | ||
| Q2 24 | $92.3M | $78.5M |
净利润CDNARMAX
| Q1 26 | $2.8M | — | ||
| Q4 25 | $-4.1M | $1.4M | ||
| Q3 25 | $1.7M | $4.0M | ||
| Q2 25 | $-8.6M | $4.7M | ||
| Q1 25 | $-10.4M | $-2.0M | ||
| Q4 24 | $87.7M | $5.8M | ||
| Q3 24 | $-10.6M | $966.0K | ||
| Q2 24 | $-4.6M | $3.7M |
营业利润率CDNARMAX
| Q1 26 | 1.0% | — | ||
| Q4 25 | -5.6% | 13.1% | ||
| Q3 25 | -0.2% | 25.0% | ||
| Q2 25 | -12.8% | 19.3% | ||
| Q1 25 | -15.8% | 7.2% | ||
| Q4 24 | 97.5% | 5.9% | ||
| Q3 24 | -16.6% | 19.4% | ||
| Q2 24 | -7.9% | 20.6% |
净利率CDNARMAX
| Q1 26 | 2.4% | — | ||
| Q4 25 | -3.8% | 2.0% | ||
| Q3 25 | 1.7% | 5.4% | ||
| Q2 25 | -9.9% | 6.4% | ||
| Q1 25 | -12.2% | -2.6% | ||
| Q4 24 | 101.3% | 8.0% | ||
| Q3 24 | -12.8% | 1.2% | ||
| Q2 24 | -5.0% | 4.7% |
每股收益（稀释后）CDNARMAX
| Q1 26 | $0.05 | — | ||
| Q4 25 | $-0.08 | — | ||
| Q3 25 | $0.03 | — | ||
| Q2 25 | $-0.16 | — | ||
| Q1 25 | $-0.19 | — | ||
| Q4 24 | $1.60 | — | ||
| Q3 24 | $-0.20 | — | ||
| Q2 24 | $-0.09 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.9M | $118.7M |
| 总债务越低越好 | — | $432.2M |
| 股东权益账面价值 | — | $452.4M |
| 总资产 | $411.1M | $582.5M |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资CDNARMAX
| Q1 26 | $77.9M | — | ||
| Q4 25 | $177.2M | $118.7M | ||
| Q3 25 | $194.2M | $107.5M | ||
| Q2 25 | $186.3M | $94.3M | ||
| Q1 25 | $230.9M | $89.1M | ||
| Q4 24 | $260.7M | $96.6M | ||
| Q3 24 | $240.9M | $83.8M | ||
| Q2 24 | $228.9M | $66.1M |
总债务CDNARMAX
| Q1 26 | — | — | ||
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | $0 | $437.2M | ||
| Q2 24 | $0 | $438.1M |
股东权益CDNARMAX
| Q1 26 | — | — | ||
| Q4 25 | $303.1M | $452.4M | ||
| Q3 25 | $311.1M | $448.1M | ||
| Q2 25 | $327.4M | $442.4M | ||
| Q1 25 | $379.3M | $433.5M | ||
| Q4 24 | $378.4M | $429.5M | ||
| Q3 24 | $273.2M | $423.1M | ||
| Q2 24 | $264.7M | $418.4M |
总资产CDNARMAX
| Q1 26 | $411.1M | — | ||
| Q4 25 | $413.2M | $582.5M | ||
| Q3 25 | $432.3M | $582.2M | ||
| Q2 25 | $444.3M | $574.8M | ||
| Q1 25 | $489.6M | $571.4M | ||
| Q4 24 | $491.1M | $581.6M | ||
| Q3 24 | $477.0M | $578.6M | ||
| Q2 24 | $466.8M | $571.4M |
负债/权益比CDNARMAX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | 0.00× | 1.03× | ||
| Q2 24 | 0.00× | 1.05× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.3M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | $514.0K | $33.5M |
| 自由现金流率自由现金流/营收 | 0.4% | 47.1% |
| 资本支出强度资本支出/营收 | — | 10.4% |
| 现金转化率经营现金流/净利润 | 1.54× | 28.39× |
| 过去12个月自由现金流最近4个季度 | — | $56.8M |
8季度趋势，按日历期对齐
经营现金流CDNARMAX
| Q1 26 | $4.3M | — | ||
| Q4 25 | $21.4M | $40.9M | ||
| Q3 25 | $37.4M | $17.7M | ||
| Q2 25 | $9.9M | $4.6M | ||
| Q1 25 | $-26.6M | $5.7M | ||
| Q4 24 | $21.9M | $59.7M | ||
| Q3 24 | $12.5M | $17.6M | ||
| Q2 24 | $18.9M | $15.9M |
自由现金流CDNARMAX
| Q1 26 | $514.0K | — | ||
| Q4 25 | — | $33.5M | ||
| Q3 25 | — | $16.4M | ||
| Q2 25 | — | $2.9M | ||
| Q1 25 | — | $4.0M | ||
| Q4 24 | — | $53.0M | ||
| Q3 24 | — | $16.3M | ||
| Q2 24 | — | $14.0M |
自由现金流率CDNARMAX
| Q1 26 | 0.4% | — | ||
| Q4 25 | — | 47.1% | ||
| Q3 25 | — | 22.4% | ||
| Q2 25 | — | 4.0% | ||
| Q1 25 | — | 5.3% | ||
| Q4 24 | — | 73.2% | ||
| Q3 24 | — | 20.8% | ||
| Q2 24 | — | 17.8% |
资本支出强度CDNARMAX
| Q1 26 | — | — | ||
| Q4 25 | — | 10.4% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | 2.3% | ||
| Q4 24 | — | 9.1% | ||
| Q3 24 | — | 1.7% | ||
| Q2 24 | — | 2.4% |
现金转化率CDNARMAX
| Q1 26 | 1.54× | — | ||
| Q4 25 | — | 28.39× | ||
| Q3 25 | 22.30× | 4.45× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.25× | 10.28× | ||
| Q3 24 | — | 18.22× | ||
| Q2 24 | — | 4.29× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDNA
| Financial Results Total | $85.0M | 72% |
| Patient and digital solutions revenue | $16.0M | 14% |
| Product revenue | $10.3M | 9% |
| Other | $6.4M | 5% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
